Send me real-time posts from this site at my email

FDA Authorizes Use of Old Malaria Drugs to Treat COVID-19

Chloroquine, a malaria treatment discovered during the 1930s, and a newer, related drug, hydroxychloroquine, have officially been authorized in the U.S. for emergency use against the novel coronavirus.

The Food and Drug Administration hasn't formally approved chloroquine and hydroxychloroquine for the treatment of COVID-19. Instead, it granted an emergency-use authorization (EUA) that allows them to be given to hospitalized coronavirus patients who can't participate in clinical trials of the drugs.

Image source: Getty Images.

Healthcare providers didn't have to wait for the EUA to attempt to treat COVID-19 patients with chloroquine or hydroxychloroquine, but the Biomedical Advanced Research and Development Authority (BARDA) needed that authorization before it could distribute those donated drugs. Some of the world's largest pharmaceutical companies, including Novartis (NYSE: NVS), and Teva Pharmaceutical (NYSE: TEVA) have already committed to donating the drugs.

Still unproven

The FDA thinks it's reasonable to conclude chloroquine-based treatments might be effective against COVID-19 based largely on the results of a study with some significant flaws. An impressive 78 out of 80 COVID-19 patients treated with a combination of hydroxychloroquine and azithromycin tested negative for the novel coronavirus five days after starting treatment.

Compared to reports from Chinese researchers, reducing the viral load for that many people in five days is remarkable. Unfortunately, we don't have any data from a placebo group, so it's hard to tell if the hydroxychloroquine was the reason they improved or if the hospital just got really lucky.

Controlled clinical trials with patients randomly placed in groups receiving chloroquine or hydroxychloroquine or placeboes are underway, and they should produce meaningful results that support or disprove the drugs' potential to treat COVID-19 before the end of April.

10 stocks we like better than Teva Pharmaceutical Industries
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Teva Pharmaceutical Industries wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of March 18, 2020

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.


Popular posts

Welcome!!! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue